45th week of 2008 patent applcation highlights part 30 |
Patent application number | Title | Published |
20080274124 | Ligand for G-protein coupled receptor GPR72 and uses thereof - The present invention relates to methods, reagents and kits for detecting of GPR72 polypeptide activity in a sample and identifying agents which modulate polypeptide activity. It further relates to antibodies raised against GPR72. It further relates to substances for preventing, treating and/or alleviating diseases or disorders characterized by dysregulation of GPR72 polypeptide signalling. | 2008-11-06 |
20080274125 | Human Stem Cell Lines Derived From Es Cells and Uses for Production of Vaccines and Recombinant Proteins - The present invention concerns the field of biology and virology. In particular, the invention concerns a method for obtaining human cell lines, in particular human stem cells derived from human embryonic stem cells, the method comprising separation from the serum, the feeder layer and at least one growth factor. The cell lines are capable of proliferating indefinitely in a basic culture medium. The invention also concerns the use of the cells derived from such cell lines for virus replication, and more particularly for producing human or veterinary vaccines, as well as for producing recombinant proteins of therapeutic interest. | 2008-11-06 |
20080274126 | Oral Vaccines for Fish - The invention relates to the development, composition and production of mucosal (oral) vaccines for fish. More specifically, the invention relates to protein complexes for the delivery of antigens to and across mucosal surfaces of fish for the induction of an immune response, and to the production of said complexes in a host cell, preferably plants. Provided is the use of a protein complex comprising an antigen of interest fused to the B-subunit of | 2008-11-06 |
20080274127 | AMINO ACID SUPPLEMENTATION FOR A HEALTHY MICROBIOTA ECOSYSTEM - The present invention pertains to a nutritional composition for reconstituting an optimal healthy microbiota ecosystem in humans or animals. In particular, the present invention relates to an ingestible carrier containing specific amino acids designed to favor the growth of bacteria favorable to individuals health or for reducing the risk of developing deleterious events. The invention also pertains to the use of specific amino acids for reconstituting an optimal healthy microbiota ecosystem in humans or animals, in particular in infants, critically ill patients, in the case of chronic diseases or any stresses impacting the gut and in elderly people. | 2008-11-06 |
20080274128 | HEAT SHOCK PROTEIN-BASED VACCINES AND IMMUNOTHERAPIES - The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious eases and cancers. | 2008-11-06 |
20080274129 | Hla-A2 Tumor Associated Antigen Peptides and Compositions - A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53. | 2008-11-06 |
20080274130 | Rabies Virus Vector Systems and Compositions and Methods Thereof - Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus. | 2008-11-06 |
20080274131 | Molecular antigen arrary - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses. | 2008-11-06 |
20080274132 | VACCINES FOR BLOCKING TRANSMISSION OF PLASMODIUM VIVAX - The present invention relates novel methods and compositions for blocking transmission of | 2008-11-06 |
20080274133 | Soluble Bifunctional Proteins - The present invention provides a soluble bifunctional protein comprising an association between a T cell receptor and a superantigen. Also provided are therapeutic compositions comprising said bifunctional proteins and methods for the use thereof. | 2008-11-06 |
20080274134 | Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex - This invention provides methods for eliciting an immune response in a subject comprising administering to the subject as part of a regimen (i) more than one dose of a nucleic acid prime, and (ii) more than one dose of a protein boost composition, wherein each dose of the nucleic acid prime is administered to the subject at a first predefined interval and each dose of the protein boost composition is administered to the subject at a second predefined interval, and wherein the protein boost composition comprises a prophylactically or therapeutically effective dose of (a) a trimeric HIV-1 gp140 protein complex, or (b) a superparamagnetic particle and a trimeric HIV-1 gp140 protein complex so affixed thereto as to permit recognition of the complex by a subject's immune system. The invention also provides methods for prophylactically or therapeutically treating HIV-1 infection in a subject. The invention further provides uses of a nucleic acid prime and a protein boost composition for the manufacture of separate coadministerable medicaments to be administered to a subject. | 2008-11-06 |
20080274135 | Measuring Degree of Polymerisation for Meningococcal Capsular Saccharides That Contain Sialic Acid - The degree of polymerisation (DP) is an important parameter for analysis of saccharide antigens, particularly in glycoconjugates. The invention provides methods that can be used to measure DP for capsular saccharides, particularly for meningococcal saccharides e.g. from serogroups W135 and Y. A preferred method is based on reduction of terminal sialic acid residues on saccharides, with DP then being calculated by comparing the molar ratio of total sialic acid to reduced sialic acid. | 2008-11-06 |
20080274136 | Polyvalent Attenuated Live Vaccine For Preventing and Curing Vibriosis of Cultivated Fish - A novel polyvalent attenuated live bacterial vaccine for preventing and curing vibriosis of cultivated fish is provided. The vaccine mainly comprises attenuated deletion strain of | 2008-11-06 |
20080274137 | DNA plasmids having improved expression and stability - The present invention relates to compositions and methods to improve expression of exogenous polypeptides, such as an antigen, epitope, immunogen, peptide or polypeptide of interest. More particularly, the present invention provides for DNA plasmids with increased expression and stability in compositions and methods useful for DNA vaccines. | 2008-11-06 |
20080274138 | Formulation of Sugar Solutions for Continuous Ultracentrifugation for Virus Purification - The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher yields and reduces unwanted aggregation of the virus or virus antigen by increasing the volume of the peak pool. | 2008-11-06 |
20080274139 | Attenuated microorganisms for the treatment of infection - The present invention pertains to a | 2008-11-06 |
20080274140 | Vaccines and Methods for Using the Same - Compositions comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with one or more of CTACK protein, TECK protein, MEC protein and functional fragments thereof and/or an isolated nucleic acid molecule that encodes an protein selected from the group consisting of: CTACK, TECK, MEC and functional fragments thereof are disclosed. Methods of inducing an immune response, including methods of inducing mucosal immune responses, in an individual against an immunogen, using such compositions are disclosed. | 2008-11-06 |
20080274141 | ANIMAL CELLS AND PROCESSES FOR THE REPLICATION OF INFLUENZA VIRUSES - Animal cells are described which can be infected by influenza viruses and which are adapted to growth in suspension in serum-free medium. Processes for the replication of influenza viruses in cell culture using these cells are furthermore described, as well as vaccines which contain the influenza viruses obtainable by the process or constituents thereof. | 2008-11-06 |
20080274142 | CHIMERIC FLAVIVIRUSES - The invention provides flavivirus vaccines and methods of making and using these vaccines. | 2008-11-06 |
20080274143 | Chloroplasts Engineering to Express Pharmaceutical Proteins - Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The vaccines are operative by parenteral administration as well. The invention also extends to the transformed plants, plant parts, and seeds and progeny thereof. The invention is applicable to monocot and dicot plants. | 2008-11-06 |
20080274144 | HCV E1 COMPRISING SPECIFIC DISULFIDE BRIDGES - The invention relates to recombinantly or synthetically produced HCV E1 envelope proteins or parts thereof comprising disulfides between specific cysteine residues. The invention further relates to viral-like particles and compositions comprising said HCV E1 envelope proteins or parts thereof as well as to methods using said HCV E1 envelope proteins or parts thereof, and to kits comprising said HCV E1 envelope proteins or parts thereof. | 2008-11-06 |
20080274145 | Deacylation of Lps in Gram Negative Bacteria - The current invention provides new Gram negative polypeptides exhibiting lipid A 3-O-deacylase activity and are capable of modifying and/or detoxifying gram negative LPS. The present invention also provides Gram negative bacteria, Gram negative bacterial lipopolysaccharides (LPS) and compositions comprising LPS, which are provided with or treated with a 3-O-deacylase activity according to the invention and which may be used for pharmaceutical and/or veterinary purposes, in particular for the preparation of whole cell or acellular vaccines against pathogenic Gram negatives such as | 2008-11-06 |
20080274146 | Application System for a Plaster Containing an Active Ingredient and a Controlled-Release Agent for Said Active Ingredient - The present invention relates to an application system for an active ingredient release system, comprising a film-form application strip, which is in each case bonded detachably to an active ingredient-containing plaster and a separate active ingredient release regulator separate there from. | 2008-11-06 |
20080274147 | Dry Limited Use Cloth - The present invention is directed to a dry cleansing cloth that comprises at least one personal care composition imparted to the cloth, wherein the composition acts as a visual indicator of the compositions depletion with each use, eventually signaling the consumer for the need of a replacement cloth. Accordingly, the cloth of the present invention may be any suitable limited use substrate, including wovens, nonwovens, films, and combinations thereof. Preferably, the limited use cloth comprises a nonwoven substrate, wherein the nonwoven substrates may include, but are not limited to airlaid fabrics, wetlaid fabrics, spunlace fabrics, spunbond fabrics, meltblown fabrics, coform fabrics, entangled spunbond fabrics, and combinations thereof. | 2008-11-06 |
20080274148 | Microcapsule Composition - The present invention comprises an oral care composition comprising a microcapsule containing a coated water soluble dye particle that is incorporated into a liquid hydrophobic material. Suitably the microcapsule containing the water soluble dye forms part of a clear gel toothpaste formulation. | 2008-11-06 |
20080274149 | Encapsulation and Controlled Release of Biologically Active Ingredients with Enzymatically Degradable Microparticulate, Hyperbranched Polymers - The invention provides encapsulated, microparticulate active ingredient formulations for the controlled release of active ingredients on skin and skin appendages consisting of encapsulation material as casing and at least one enclosed biologically active ingredient as core, which is characterized in that enzymatically degradable organic hyperbranched polymers containing ester groups are used as encapsulation material. | 2008-11-06 |
20080274150 | Process For Removing Odors From Hydrocarbons - A process for removing odors from hydrocarbons is disclosed. Odor-free hydrocarbons obtained by the process are described, which hydrocarbons are particularly suitable for use in cosmetic applications. Cosmetic formulations which contain the odor-free hydrocarbons are also described. | 2008-11-06 |
20080274151 | COSMETIC COMPOSITION - A cosmetic composition comprising a cosmetic base selected from the group consisting of liquid base, paste base and powder base, a perfume ingredient, and polyamide particles wherein the polyamide particles comprise at least either of the porous polyamide particles of the following (1) and (2) shows satisfactory shape retention on human skin, excellent light-scattering properties to diminish abnormal light reflection on human skin surface, and excellent oil-absorbing properties to effectively absorb lipid oozing from human body when it is applied to human skin: (1) spherical porous polyamide particles having a number average particle diameter of 1 to 30 μm, a BET specific surface area of 5 m | 2008-11-06 |
20080274152 | COSMETIC POWDER COMPOSITIONS HAVING LARGE PARTICLE SIZE COLOR TRAVEL EFFECT PIGMENTS - A cosmetic composition preferably in powder form comprising pigments having a color travel effect, wherein said composition contains a sufficient amount of large particle size color travel pigments having a D50 particle size of at least 40 μm up to about 150 μm to retain the color travel effect upon application to skin. | 2008-11-06 |
20080274153 | Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations - An animal-derived lipid is disclosed that is useful as a carrying agent for anti-microbial formulations. Pharmaceutical and other preparations including Emu Oil are also described as profoundly useful components in anti-bacterial, anti-fungal, and anti-viral treatments. This lipid material is extracted from the Emu ( | 2008-11-06 |
20080274154 | Water-based, antimicrobially active, dispersion concentrates - Highly concentrated, water-based dispersions of certain lipophilic and/or hydrophobic antimicrobially active materials are stabilized to a surprising degree by a surfactant combination including a nonionic acrylic graft copolymer surfactant and a alkoxylated polyarylphenol phosphate ester surfactant. The active materials may be present in dispersion concentrates of the present invention singly or in useful combinations. The active materials are selected from the group of fungicides and bactericides consisting of 1,2-benzisothiazol-3(2H)-one; 2-octyl-2H-isothiazol-3-one; 5-chloro-2-methyl-2H-isothiazol-3 -one; 2-methyl-2H-isothiazol-3-one; pyrithione zinc; 3-iodo-2-propynyl butylcarbamate; 2-methylthio-4-ethylamino-6-tert-butylamino-s-triazine; and 3-(4-isopropylphenyl)-1,1-dimethylurea, and mixtures thereof. The dispersion concentrates may be efficiently shipped and stored, and subsequently diluted with water to produce less concentrated dispersions when desired. Even at relatively high concentrations, the dispersion compositions of the present invention can be stored for months or years without significant loss of stability. | 2008-11-06 |
20080274155 | Chimeric Cannulae Proteins, Nucleic Acids Encoding Them And Methods For Making And Using Them - The invention provides chimeric cannulae polypeptides and nanotubules and methods for making and using them. In one aspect, the invention provides compositions and methods for the identification, separation or synthesis of proteins or ligands. In one aspect, the invention provides compositions and methods for making and using nanotubules. In one aspect, the invention provides compositions and methods for the selection and purification of chiral compositions from racemic mixtures. In one aspect, the chimeric proteins and polymers (e.g., nanotubules, tubules, bundles, balls, fibers, filaments, sheets, threads, textiles) of the invention comprise a detectable moiety, e.g., a fluorescent protein. In one aspect, the invention provides a flame retardant or heat resistant device comprising a sheeting, a covering, a coating or an adhesive comprising a chimeric protein of the invention. | 2008-11-06 |
20080274156 | Composition forstimulating bone growth and differentiation and method for isolating same - This invention relates to isolated heparan sulphate and use thereof to stimulate bone cell growth and differentiation. The invention also relates to use of heparan sulphate with implants, prosthesis and bioscaffolds to repair and regenerate bone. Such use may be for repair of damaged tissue including bone tissue, for example damage resulting from injury or defect. | 2008-11-06 |
20080274157 | Cartilage implant plug with fibrin glue and method for implantation - The invention is directed toward a cartilage repair assembly comprising a shaped structure of subchondral bone with an integral overlying cartilage cap which is treated to remove cellular debris and proteoglycans and milled cartilage in a bioabsorbable carrier. The shaped structure is dimensioned to fit in a drilled bore in a cartilage defect area so that said shaped bone and cartilage cap when centered in the bore does not engage the side wall of the bore and is positioned from the side wall of the bone a distance ranging from 10 microns to 1000 microns and is surrounded by milled cartilage and a fibrin thrombin glue. A method for inserting the assembly into a cartilage defect area is disclosed. | 2008-11-06 |
20080274158 | Hydrazide Compounds with Angiogenic Activity - Compounds exhibiting angiogenic properties incorporating the structure of Formula I: | 2008-11-06 |
20080274159 | DRUG FORMULATIONS FOR COATING MEDICAL DEVICES - The present invention relates to oil-based formulations of hydrophobic drugs for the uniform coating of medical devices such as vascular stents and balloons. Another aspect of the present invention is an intravascular medical device having an oil-based coating suitable for delivering a water-insoluble drug, comprising one or more of an anti-oxidant, an anti-inflammatory and an anti-restenotic agent. | 2008-11-06 |
20080274160 | Implant material - An implant material includes a base material that includes, as a main component, a partially stabilized zirconia having an average crystal particle diameter of 0.3 μm or less and a porous covering layer that includes ceramic as a main component and has a center pore diameter within a range of 10-100 μm. The covering layer | 2008-11-06 |
20080274161 | HYDROGELS AND HYDROGEL PARTICLES - The invention provides fabricated hydrogels, hydrogel particles, hydrogel containing compositions, and methods of making the same. The invention also provides methods of implanting, injecting, or administering the hydrogels, hydrogel particles, or the hydrogel containing compositions to treat a subject in need. Methods of crosslinking pre-solidified or pre-gelled hydrogel particles and making crosslinked hydrogels, crosslinked hydrogel particles, and crosslinked hydrogel containing compositions also are disclosed herein. | 2008-11-06 |
20080274162 | Method, composition, and delivery mode for treatment of prostatitis and other urogenital infections using a probiotic rectal suppository - This invention is a probiotic composition using the delivery mode of a rectal suppository for the treatment and relief of symptoms of urogenital infections including prostatitis. This invention is unique in both mode of delivery and in enabling the treatment of such urogenital infections as prostatitis. The present invention discloses compositions, methodologies, and delivery mode for the utilization of probiotic organisms in therapeutic compositions for treatment and relief from the symptoms of urogenital infections by maintaining and restoring normal flora in humans. The composition includes one or more bacteria selected from the genus | 2008-11-06 |
20080274163 | Nose and throat anti-influenza solution and method of use - A nose and throat anti-influenza solution is described that decreases the likelihood influenza infection and its spread. The solution's components are readily available and have been used to treat humans for other ailments previously, leading to an easily implemented, scalable, safe, and cost-effective solution. The core components of the solution include: specially denatured alcohol (SDA); Triton x-100; sodium saccharin; 1,8 cineole (eucalyptol); thymol; methyl salicylate; menthol; sorbitol and/or glycerin; sodium benzoate; poloxamer 407; polysorbate 80; and distilled water. Optionally, the solution also includes one or more of the following: citric acid; | 2008-11-06 |
20080274164 | Atrium Patch - The invention relates to a plaster composition for administering active agents in and to bodily orifices, such as e.g. the buccal cavity, lips or genitalia. | 2008-11-06 |
20080274165 | WOUND HEALING COMPOSITIONS CONTAINING KERATIN BIOMATERIALS - Disclosed are keratin preparations for use in medical applications. Methods of treating wounds are provided, wherein keratin preparations are applied to the wound in a treatment effective amount. Methods of treating burn wounds are also provided. Surgical or paramedic aids are provided, comprising a substrate with keratin preparations provided thereon. Kits comprising keratin derivatives packaged in sterile form are also provided. | 2008-11-06 |
20080274166 | Patch for Transdermal Drug Delivery - Apparatus is provided including a transdermal drug delivery patch product (10, 100), which includes a patch ( | 2008-11-06 |
20080274167 | TRANSDERMAL THERAPEUTIC SYSTEM (TTS) WITH FENTANYL AS ACTIVE INGREDIENT - The invention relates to transdermal therapeutic systems with fentanyl or an analogous fentanyl derivative as active ingredient. In order to prevent inadvertent overdosage by uncontrolled release of active ingredient as a result of damage, the active ingredient is contained in fluid-filled micro-reservoirs in the layer containing the active ingredient. The layer containing the active ingredient can optionally be provided with a membrane. | 2008-11-06 |
20080274168 | TRANSDERMAL DELIVERY DEVICE DISPOSAL SYSTEM - The present invention relates to a transdermal delivery device disposal system for disposing of a transdermal delivery device containing at least one pharmaceutically active component. The disposal system contains at least one sheet or substrate on which an adhesive is coated; and one or more of the following components: (a) monomer, and optionally comonomer(s), to be polymerized; (b) an initiator, and optionally co-initiator(s), to initiate the polymerization; (c) at least one crosslinking agent to crosslink the (co)polymer; and (d) at least one deactivating agent to chemically alter, to degrade, and/or to deactivate the active component(s) contained in the transdermal delivery device, such as an opioid antagonist or an opioid agonist deactivating agent so that the euphoric effects of the active component(s) contained in the transdermal delivery device are at least temporarily inhibited, diminished, or halted in vivo, wherein at least one adhesive-coated sheet or substrate adheres to, immobilizes, or isolates, and prevents, inhibits, or diminishes the misuse or abuse of the active component contained in, at least one transdermal delivery device. | 2008-11-06 |
20080274169 | Photosensitizer formulations for topical applications - Highly flexible penetrating liposomal carrier systems are formulated with enhanced skin penetration properties. These specialized formulations of highly flexible penetrating liposomal delivery systems comprise one or more phospholipids, lysophosphatides and hydrophobic photosensitizer. This new formulations can squeeze liposomal particles through intercellular regions of stratum corneum as intact structures, and, in this way, deliver encapsulated photosensitizer to the epidermis, dermis, hypodermis and surroundings. The penetrating liposomal formulation provides therapeutically effective amounts of the hydrophobic photosensitizer through topical application with better skin penetration thus improving drug targeting and the efficacy of photodynamic therapy (PDT). | 2008-11-06 |
20080274170 | PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 2008-11-06 |
20080274171 | Renin Inhibitors Nitroderivatives - Renin inhibitors nitroderivatives of formula (I): | 2008-11-06 |
20080274172 | Liposome Preparation Method - The invention relates to a method for preparing liposomes with at least two uniformly distributed phospholipids without using organic solvents. | 2008-11-06 |
20080274173 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS - The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. | 2008-11-06 |
20080274174 | STABLE PANCREATIC ENZYME COMPOSITIONS - Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing. | 2008-11-06 |
20080274175 | Compositions Comprising Edible Oils and Vitamins and/or Minerals and Methods for Making the Compositions - The invention provides compositions for an administration to a mammal orally or in a suppository that include one or more edible oils (preferably including one or more omega-3 fatty acids), one or more plant stanols, phytosterols, or esters thereof, and admixed in the one or more edible oils one or more water-soluble vitamins and/or minerals, for example, vitamins B6, B9 and/or B12. The invention also provides a method of making the compositions comprising mixing the foregoing components to form a suspension or emulsion of the vitamins and/or minerals in the edible oils. The mixture can be inserted into hollow soft or hard capsules, gelcaps or caplets. The edible oils can coat particles of the water-soluble vitamins and/or minerals, which may provide them with an improved absorption in the body due to an increased resistance to degradation in the acidic environment of the stomach. | 2008-11-06 |
20080274176 | Pharmaceutical Lipid Compositions - The present invention relates to a particulate composition containing; a) 5 to 90% of at least one phosphatidyl choline component b) 5 to 90% of at least one diacyl glycerol component, at least one tocopherol, or mixtures thereof, and c) 1 to 40% of at least one non-ionic stabilising amphiphile, where all parts are by weight relative to the sum of the weights of a+b+c and where the composition contains particles of at least one non-lamellar phase structure or forms particles of at least one non-lamellar phase structure when contacted with an aqueous fluid. The invention additionally relates to pharmaceutical formulations containing such compositions, methods for their formation and methods of treatment comprising their administration. | 2008-11-06 |
20080274177 | CONTROLLED RELEASE DOSAGE FORMS - The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups. | 2008-11-06 |
20080274178 | Orally Disintegrating Tablet - By mixing an active ingredient, crystalline cellulose, an inorganic excipient, carmellose, and a lubricant at not more than 0.8% by weight per tablet, and compressing the mixture, or compressing the mixture by an external lubricating method, a palatable orally disintegrating tablet which maintains a tablet hardness and exhibits good disintegrating property can be obtained. | 2008-11-06 |
20080274179 | Supercritical CO2 liquorice extract and products made there from - The present invention provides, in one aspect, to products made from a novel and non-obvious supercritical CO | 2008-11-06 |
20080274180 | Extended Release Pharmaceutical Composition of Metformin and a Process for Producing It - A pharmaceutical composition in the form of tablets constitutes an orally administered, controlled drug delivery system that will provide increased retention time of the device in the stomach over conventional dosage forms and release metformin or its pharmaceutically acceptable salt in a controllable manner, and further that is easy and inexpensive to manufacture. | 2008-11-06 |
20080274181 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS - Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described. | 2008-11-06 |
20080274182 | Tablet coatings made from modified carboxymethylcellulose materials - Coated tablets for the delivery of active ingredients to a user are provided. Such tablets include particular molecular weight-modified carboxymethylcellulose (CMC) coating materials either alone or in combination with other types of hydrocolloids, biogums, cellulose ethers, and the like. The utilization of such modified CMC products aids in the production of such coatings through the availability of larger amounts of base materials with lower amounts of water requiring evaporation therefrom. In such a manner, not only may dimensionally stable, non-tacky, salt tolerant, and quick dissolving edible coatings be produced, but the amount of time required for such manufacture is minimal when compared with traditional methods of production with -based materials. Furthermore, such novel edible non-digestible tablet coatings exhibit delayed dissolution beyond a user's oral cavity for tastemasking purposes, as well as protection of the tablet from environmental conditions and low tackiness properties to prevent adhesion to the user's palate. The novel method of tablet coating manufacture as well as the ultimate coated tablets exhibiting such physical characteristics are also encompassed within this invention. | 2008-11-06 |
20080274183 | Thermoplastic articles containing a medicament - A composition suitable for making a fiber or a film includes a biocompatible primary polymer matrix which forms a continuous phase of the composition and an active agent forming a substantially discontinuous phase of the composition. The biocompatible primary polymeric matrix has a glass transition temperature of less than about 100° C. and is impermeable to the active agent. A process for making an article, such as a fiber or a film, includes the steps of providing a polymer blend comprising a polymer matrix having from 99.9 weight % to about 30 weight % of a biocompatible polymeric matrix and from about 0.1 to about 70 weight % of an active agent, wherein the weight % are based on the total weight of the of the polymeric matrix and active agent, and extruding the polymer blend into the article. | 2008-11-06 |
20080274184 | Ecm-Based Graft Material - This invention is directed to graft materials comprising an extracellular matrix (ECM) and therapeutic agents. This invention is also directed to methods of using the graft materials for healing of damaged or diseased tissues on a patient's body. | 2008-11-06 |
20080274185 | Shape and Dimension Maintenance of Soft Tissue Grafts by Stem Cells - Methods and compositions for de novo and in vivo synthesis of soft tissue in predefined shape and dimensions from adult mesenchymal stem cells (MSC | 2008-11-06 |
20080274186 | NELL-1 enhanced bone mineralization - Provided herein are methods for enhancing bone mineralization for bone repair or regeneration and compositions and grafts therefor. Methods for screening agents that enhance or modulate NELL-1 gene expression or NELL-1 protein production in a cell are also provided. | 2008-11-06 |
20080274187 | Hard capsule composition and method of use - A hard shell capsule composition and method which is gelatin, BSE, plasticizer and preservative free, which is less sensitive to temperature, humidity and climate changes during manufacture and storage while remaining dimensionally and microbially stable. | 2008-11-06 |
20080274188 | Oral Vehicle For Systemic Pharmaceuticals - Systemic drug delivery includes boluses of a semi-solid agar gel, each containing active ingredients, packed singly or in co-operating sets in blister packs, or loose in a container. When placed in the mouth the bolus is disrupted, comes apart, and releases the active ingredients. Sialogogues, flavours, and other additives assist in swallowing. Grains of the active ingredients may be encapsulated inside harder gel capsules. Active ingredients include over-the-counter medications and prescription medications. Applications include self-medication particularly in water—free situations such as public transport, medication for children, stroke victims or the aged. | 2008-11-06 |
20080274189 | Organic Compounds Comprising a Glycopyrr Onium Salt - Medicaments comprising (A) an antimuscarinic agent and (B) a corticosteroid for the treatment of inflammatory or obstructive airways diseases. | 2008-11-06 |
20080274190 | TEMPERATURE AND pH - SENSITIVE BLOCK COPOLYMER HAVING EXCELLENT GEL STRENGTH, METHOD OF PREPARING THE SAME, AND DRUG DELIVERY SYSTEM USING THE SAME - Disclosed herein is a temperature- and pH-sensitive block copolymer having excellent gel strength, including: (a) a poly(ethylene glycol)-based compound (A) or a copolymer (B) of the poly(ethylene glycol)-based compound (A) and a biodegradable polymer; and (b) a polyurethane-based oligomer (C). Further, a method of preparing a temperature and pH-sensitive block copolymer having excellent gel strength, including: (a) synthesizing a poly(ethylene glycol)-based compound (A) or a copolymer (B) of the poly(ethylene glycol)-based compound (A) and a biodegradable polymer; and (b) coupling a polyurethane-based oligomer (C) with the copolymer (B), is disclosed. Also disclosed is a polymer hydrogel type drug delivery system, including: (a) the block copolymer; and (b) a physiologically active substance which can be included in the block copolymer. | 2008-11-06 |
20080274191 | Bioadhesive Composition With Programmed Release - The invention relates to novel viscous liquid compositions for producing pasty forms having a prolonged action and/or release for local applications. These compositions are characterized in that the long-lasting action and/or the prolonged release of the active substance is obtained by the in-situ formation of a matrix film having an increased bioadhesive power and being more or less viscous and biodegradable. The invention also relates to a viscous liquid composition with an increased bioadhesive power for a local application in pasty form with a prolonged release of an active substance, whereby being characterized in that it contains at least one matrix agent, a medium for hydrating the matrix agent, and at least one active substance. | 2008-11-06 |
20080274192 | Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor - A pharmaceutical composition comprising the compound 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, or a pharmaceutically acceptable salt or solvate thereof, in an amorphous form. | 2008-11-06 |
20080274193 | Retinoic Acid-Containing Antidiabetic Agent - The present invention aims to provide a novel agent for treating and/or preventing diabetes which agent can not only control a blood sugar level but also fundamentally treat a patient with type I diabetes suffering from destruction of β cells and a patient with type II diabetes suffering from dysfunction in insulin secretion. The present invention provides an agent for treating and/or preventing diabetes, the agent containing retinoic acid as an active ingredient. Retinoic acid incorporated as an active ingredient may be all-trans retinoic acid, an isomer thereof, a derivative thereof, a salt thereof or a prodrug thereof. Retinoic acid may be incorporated singly. Alternatively, composite particles of retinoic acid and an appropriate inorganic or organic substance are prepared, and the retinoic acid composite particles may be incorporated. | 2008-11-06 |
20080274194 | Stabilized Hme Composition With Small Drug Particles - A hot-melt extruded composition having finely divided drug-containing particles dispersed within a polymeric and/or lipophyllic carrier matrix is provided. The carrier softens or melts during hot-melt extrusion but it does not dissolve the drug-containing particles during extrusion. As a result, a majority or at least 90% wt. of the drug-containing particles in the extrudate are deaggregated during extrusion into essentially primary crystalline and/or amorphous particles. PEO is a suitable carrier material for drugs insoluble in the solid state in this carrier. Various functional excipients can be included in the carrier system to stabilize the particle size and physical state of the drug substance in either a crystalline and/or amorphous state. The carrier system is comprised of at least one thermal binder, and may also contain various functional excipients, such as: super-disintegrants, antioxidants, surfactants, wetting agents, stabilizing agents, retardants, or similar functional excipients. A hydrophilic polymer, such as hydroxypropyl methylcellulose (HPMC E15), polyvinyl alcohol (PVA), or poloxamer, and/or a surfactant, such as sodium lauryl sulfate (SLS), can be included in the composition. A process for preparing the extrudate is conducted at a temperature approximating or above the softening or melting temperature of the matrix and below the point of solubilization of drug-containing particles in the carrier system, and below the recrystallization point in the case of amorphous fine drug particles. | 2008-11-06 |
20080274195 | Compositions and Methods for Making and Using Nanoemulsions - The present invention discloses an improved nanoemulsion comprising a uniform and discrete range of very small particle nano-sized diameters. This uniformity results in improved bioavailability of incorporated compounds (i.e., pharmaceuticals or nutraceuticals) as reflected in various pharmacokinetic parameters including, but not limited to, decreased T | 2008-11-06 |
20080274196 | Oral Pharmaceutical Suspension Compositions Of Fexofenadine - An oral, pharmaceutical suspension composition of Fexofenadine. Fexofenadine is a mixture of compacted Fexofenadine and plain fexofenadine in a ratio of 0.01:0.99 to 0.99 to 0.01 having a mean particle size of fexofenadine particles in the range of 10μ and 250 μ.An oral, pharmaceutical suspension composition of Fexofenadine, which is bioequivalent to a tablet dosage form of fexofenadine marketed under the trade name of Allegra®. Bioequivalence between a suspension formulation and the commercially tablet formulation of fexofenadine i.e. ‘Allegra®’ is achieved by the use of a mixture of compacted Fexofenadine. | 2008-11-06 |
20080274197 | LYOPHILIZED FORMULATION - For clinical application of cis[((1R,2R)-1,2-cyclohexanediamine-N,N′)bis(R | 2008-11-06 |
20080274198 | USE OF MULTILAYERED PIGMENTS IN THE FOOD AND PHARMACEUTICALS SECTOR - The present invention relates to the use of multilayered pigments based on platelet-shaped substrates for colouring food and pharmaceutical products. | 2008-11-06 |
20080274199 | CONTROLLED RELEASE CERAMIC PARTICLES, COMPOSITIONS THEREOF, PROCESSES OF PREPARATION AND METHODS OF USE - Controlled release ceramic particles, processes for their preparation, controlled release ceramic particles prepared by such processes, compositions comprising such controlled release ceramic particles and methods of using controlled release ceramic particles are described. In one form each of the controlled release ceramic particles has an active material(s) substantially homogeneously dispersed throughout the particles, wherein the active material(s) is capable of being released from said particles, and the active material(s) in said particles is substantially protected from degradation until release of the active material(s) from the particles. | 2008-11-06 |
20080274200 | DOSE TITRATABLE LIQUID DOSAGE FORMS OF ACID LABILE DRUGS - Provided herein are pharmaceutical formulations comprising micro-granules and a liquid suspension vehicle having a pH less than 6.0 and a viscosity sufficient to suspend the micro-granules. The micro-granules typically contain a PPI which therefore makes the above formulation, as well as kits for making the above formulation, useful for alleviating the symptoms of gastrointestinal disorders or diseases. | 2008-11-06 |
20080274201 | GELS FOR ENCAPSULATION OF BIOLOGICAL MATERIALS - This invention provides novel methods for the formation of biocompatible membranes around biological materials using photopolymerization of water soluble molecules. The membranes can be used as a covering to encapsulate biological materials or biomedical devices, as a “glue” to cause more than one biological substance to adhere together, or as carriers for biologically active species. Several methods for forming these membranes are provided. Each of these methods utilizes a polymerization system containing water-soluble macromers, species, which are at once polymers and macromolecules capable of further polymerization. The macromers are polymerized using a photoinitiator (such as a dye), optionally a cocatalyst, optionally an accelerator, and radiation in the form of visible or long wavelength UV light. The reaction occurs either by suspension polymerization or by interfacial polymerization. The polymer membrane can be formed directly on the surface of the biological material, or it can be formed on material, which is already encapsulated. | 2008-11-06 |
20080274202 | Compositions and Method for Brain Specific Targeted Delivery of Therapeutic Agents - Disclosed are methods and compositions for delivering a therapeutic agent to target organs or tissues, such as brain. The methods and compositions use bone marrow stem cells, monocytes, macrophages or microglial cells to deliver the therapeutic agent associated with nanoparticles to the target organ or tissue. | 2008-11-06 |
20080274203 | BIOEFFECTIVE KRILL OIL COMPOSITIONS - This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO | 2008-11-06 |
20080274204 | Ultra Fine Dead Sea Mineral Compound and Method of Manufacture - An ultra fine mineral compound and method of processing native Dead Sea minerals into this ultra fine mineral compound that can be used to manufacture all natural Dead Sea mineral compositions particularly compositions for use in bath and body products is disclosed. Even with the extreme ionic character of the Dead Sea minerals, the Dead Sea mineral compositions prepared remain in suspension creating a viable cosmetic preparation that can maintain adequate shelf life and provide a more pleasant feel for the consumer. | 2008-11-06 |
20080274205 | Ena Mineral Bioactive Solution, Manufacturing Method Thereof and Its Application for the Osteoporosis Prevention - The present invention is related to a method of manufacture of an alkaline mineral bioactive solution of which raw materials are squid bones burnt at a high temperature and crushed powder of red seaweeds and to compositions and health foods having the efficacy for the prevention of osteoporosis. The alkaline aqueous solutions having abundant minerals of the present invention may be used for bioactive solutions having the efficacy for the prevention and improvement of osseous diseases such as osteolysis and osteoporosis in mammals including human beings. | 2008-11-06 |
20080274206 | Stabilised Oxygen Releasing Composition - The present invention relates to stabilised liquid oxygen releasing composition comprising a component (a) selected from the salts consisting of cations A | 2008-11-06 |
20080274207 | ANTIMICROBIAL LENSES, PROCESSES TO PREPARE THEM AND METHODS OF THEIR USE - This invention relates to solutions for packaging ophthalmic devices comprising at least one antimicrobial metal salt which prevent the loss of said antimicrobial metal salt during autoclaving and storage. | 2008-11-06 |
20080274208 | Water treatment containing DBNPA for use in sanitizing recreational water - The present invention is directed to a composition for reducing the levels of microorganisms in recreational water systems, comprising: (1) a biocidal effective amount of dibromonitrilopropionamide (DBNPA); (2) optionally, a biocidal effective amount of an algaecide selected from the group consisting of didecyldimethylammonium chloride (DDAC), zinc, and copper; and (3) optionally, a compound capable of in situ activation to form an oxidizing agent; wherein the composition is effective for reducing the levels of microorganisms in recreational water systems. The present invention is also directed to a method of controlling the growth of microorganisms in recreational water systems, comprising the step of providing the above composition; and adding the composition to a recreational water system. | 2008-11-06 |
20080274209 | METHODS OF TREATING INFLAMMATION - Disclosed are compositions containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients), and a pharmaceutical carrier. Also disclosed are methods of treating inflammatory symptoms and lesionous symptoms of a viral infection involving applying an effective amount of the pharmaceutical composition to the inflammation and lesions. | 2008-11-06 |
20080274210 | Pharmaceutical-Grade Ferric Organic Compounds, Uses Thereof and Method of Making Same - The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels. | 2008-11-06 |
20080274211 | Methods and Compositions for Controlling Micororganism Populations in the Digestive System of Animals - The invention is related to methods and compositions for controlling microorganism populations in the digestive system of an animal. In an embodiment, the invention is a composition for reducing the bacterial load in the digestive tract of an animal including a saponin containing composition and an anti-microbial agent. Other embodiments are included herein. | 2008-11-06 |
20080274212 | Herbal Extract for Renal Disorders - The present invention relates to the use of standardized extract of | 2008-11-06 |
20080274213 | Drug for Ameliorating Male Climacteric Disorders - It is intended to provide a highly safe pharmaceutical drug or food that inhibits reduction in blood testosterone level and prevents or ameliorates symptoms and so on associated with male climacteric disorders. The present invention provides a drug for inhibiting reduction in blood testosterone level and a drug for ameliorating male climacteric disorders comprising a plant belonging to the genus | 2008-11-06 |
20080274214 | Medicament For The Prevention and Treatment Of Influenza - The invention relates to the use of an extract from plants of the genus | 2008-11-06 |
20080274215 | COMPOSITION FOR TREATMENT OF COLD AND FLU - The present invention is a composition delivering therapeutically effective amounts of | 2008-11-06 |
20080274216 | Preparation, process and a regenerative method and technique for prevention, treatment and glycemic control of diabetes mellitus - A medicinal preparation, a process, a nutritional composition and regenerative and insulin potentiating method for humans and also for mammals for prevention, treatment and management/glycemic control of diabetes mellitus by obtaining optimum glucose level in blood, by administering an extract of | 2008-11-06 |
20080274217 | Oral Compositions and Route of Administration for the Delivery of a Thylakoid Extract - The present invention provides a new use for a thylakoid extract, that is for oral route of administration, and a composition comprising the thylakoid extract in adjunction with an acceptable carrier for oral administration. Besides the pharmaceutical use, the thylakoid extract enters the composition of food or food supplements, for its inocuity and its capacity to provide a diet enriched in anti-oxidants and anti-inflammatory compounds. Therefore, in accordance with the present invention is provided the use of a thylakoid extract in the making of an oral composition for treating or preventing a disease or disorder involving the formation of reactive oxygen species or inflammation. Also is provided a method for treating or preventing a disease or disorder involving the formal of reactive oxygen species or inflammation in an individual, which comprises the step of orally administering an effective dose of a thylakoid extract. Further is provided an oral composition comprising a thylakoid extract and a vehicle for oral ingestion or oral administration. An oral composition comprising purified thylakoids and a carrier for oral ingestion or oral administration, with the proviso that the carrier does not essentially consists of water, physiological saline or propylene glycol is also provided as food or a food supplement, or as a pellet, or encapsulated granules or powder. The carrier may be present in an amount of 0.01% to 95% (w/w) of the total composition. The purified thylakoids are present in an amount which achieves a dosage of 0.1 to 10 mg per Kg of a subject's body weight. | 2008-11-06 |
20080274218 | Gnetum Extract | 2008-11-06 |
20080274219 | Method and apparatus for making foot impressions - A method and apparatus for the making of an impression of a person's foot in foam to be used in the manufacture of orthotics comprising in combination a box of foam that will be deformed by the person's foot during the making of a foot impression, placed in foam box receptacle that is supported on a base and which can adjustably swivel or rotate so that the person's knee, ankle and foot will be put in a neutral position and when in use the person is placed in a seated position and a box of foam is placed in the receptacle and a strap assembly is used to exert a downward force on the person's lower leg, the strap being secured to a lever arm used to exert a downward pressure and engage with a block arm which correspondingly exerts a downward force on a block situated above the box of foam and which pushes the foot down into the foam and wherein the block is slideable transversely to the box of foam to align with the arch of the person's foot and to insure that the block exerts its downward pressure evenly and directly on the person's foot. | 2008-11-06 |
20080274220 | Portable Concrete Moulding Machine - A portable concrete molding machine can extrude concrete moldings of a range of widths by the provision of one or more tunnel plates within the mold, the machine being provided with respective pusher plates that have pusher faces of widths complementary to the effective widths of the mold. A pair of links connect a gearbox to the pendulum arms of the pusher means to ensure even driving force applied to the pusher plates as they undergo reciprocating movement to allow concrete to flow from a hopper through a mouth of the mold and to extrude the concrete from the mold, the machine being advanced in an extrusion direction by the extrusion of the concrete from the mold. | 2008-11-06 |
20080274221 | MACHINE FOR PROCESSING RESIDUAL MATERIAL - The invention relates to a machine for processing residual material, comprising at least one actuator which acts mechanically upon the residual material and at least a portion of the surface of which is movable relative to a corresponding surface of an adjacent component of the machine. | 2008-11-06 |
20080274222 | Decoupled transverse flow metering gap and lip gap - The present invention provides a slot die that includes a flow passageway that includes a transverse flow-providing manifold, a flow metering section that provides a transverse flow metering gap, and an exit channel that includes an exit orifice. In accordance with the invention, the transverse flow metering gap may beneficially be selected independent of changing the gap or width of the exit office, using one or more normally non-adjustable die bodies. | 2008-11-06 |
20080274223 | Decoupled transverse flow metering gap and lip gap - The present invention provides a slot die that includes a flow passageway that includes a transverse flow-providing manifold, a flow metering section that provides a transverse flow metering gap, and an exit channel that includes an exit orifice. In accordance with the invention, a transverse flow metering gap may beneficially be selected independent of changing the gap or width of the exit office, using one or more normally non-adjustable die bodies. | 2008-11-06 |